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Formation of hepatocyte Mallory-Denk bodies (MDBs), which are aggregates of keratins
8 and 18 (K8/K18), ubiquitin, and the ubiquitin-binding protein, p62, has a genetic pre-
disposition component in humans and mice. We tested the hypothesis that metabolomic
profiling of MDB-susceptible C57BL and MDB-resistant C3H mouse strains can illumi-
nate MDB-associated pathways. Using both targeted and unbiased metabolomic analyses,
we demonstrated significant differences in intermediates of purine metabolism. Further
analysis revealed that C3H and C57BL livers differ significantly in messenger RNA
(mRNA) level, protein expression, and enzymatic activity of the adenosine-generating
enzyme, ecto-50-nucleotidase (CD73), which was significantly lower in C57BL livers.
CD73 mRNA levels were also dramatically decreased in human liver biopsies from hepati-
tis C and nonalcoholic fatty liver disease patients. Feeding mice with a diet containing the
MDB-inducing agent, 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), significantly
decreased CD73 protein and activity in C57BL livers and resulted in loss of plasma mem-
brane CD73 expression and activity in isolated mouse hepatocytes. To further examine
the role of CD73 in MDB formation in vivo, we fed wild-type (WT) and CD732/2 mice
a DDC-containing diet. Liver enlargement, p62 induction, and disappearance of the K8/
K18 cytoskeleton were attenuated in CD732/2, compared to WT livers. MDB formation,
as assessed by biochemical and immunofluorescence detection of keratin and ubiquitin
complexes, was nearly absent in CD732/2 mice. Conclusion: Purine metabolism and
CD73 expression are linked to susceptibility to MDB formation in livers of different
mouse strains. Expression of the adenosine-generating enzyme, CD73, contributes to
experimental MDB induction and is highly regulated in MDB-associated liver injury in
mice and in chronic human liver disease. (HEPATOLOGY 2013;58:1790-1800)
M
allory-Denk bodies (MDBs) are intracellular
aggregates of hepatocytes that contain the
cytoskeletal intermediate filament proteins,
keratins 8 and 18 (K8/K18), as their major components,
in addition to ubiquitin, and the ubiquitin-binding pro-
tein, p62.1 Cross-linking of keratins, particularly K8, by
transglutaminase 2 (TG2) is critical for MDB forma-
tion.2,3 MDBs are frequently observed alongside hepa-
tocyte ballooning and loss of the cytoplasmic K8/K18
intermediate filament network.4 Livers of patients with
alcoholic and nonalcoholic steatohepatitis most fre-
quently display MDBs as part of their pathology,5 where
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MDB presence correlates with less-favorable out-
comes.6,7 MDBs are also observed in the context of
hepatocellular carcinoma, viral hepatitis, and some
forms of drug-induced liver injury.1,8 However, MDBs
are not observed in all patients with the same liver dis-
ease,9,10 and increases in their formation over time are
associated with decompensation and progression to cir-
rhosis in patients with hepatitis C virus (HCV) infec-
tion.11 Identification of the factors that regulate or
contribute to MDB formation may yield important
insights into the general role of protein aggregation in
liver disease pathogenesis.
Different strains of mice exhibit varying susceptibility
to experimental MDB induction upon administration
of the porphyrogenic compound, 3,5-diethoxycarbonyl-
1,4-dihydrocollidine (DDC),12 a long-standing model
reflective of the major biochemical and ultrastructural
features of human MDBs.1 These strain differences are a
useful paradigm for uncovering contributing factors to
protein aggregation in hepatocytes, beyond the already
known roles for protein misfolding and proteasomal
inhibition.13,14 Comparison of MDB-susceptible
(C57BL) to MDB-resistant (C3H) mice at the proteo-
mic level revealed major differences in the energy metab-
olism and oxidative-stress-sensitive enzymes,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and nucleoside diphosphate kinase (NDPK).15 Given
the critical housekeeping functions of GAPDH in gly-
colysis and NDPK in nucleotide (nt) metabolism, we
hypothesized that these two strains also exhibit differen-
ces in their liver metabolomes that may ultimately affect
their response to liver injury caused by DDC.
In the present study, we performed both targeted and
unbiased metabolomic analyses to compare C3H and
C57BL mouse livers, which ultimately led us to
identify ecto-50-nucleotidase (CD73) as a modulator of
MDB formation in mouse liver. CD73 is a
glycosylphosphatidylinositol-linked, membrane-bound
glycoprotein that catalyzes the phosphohydrolysis of adeno-
sine 50-monophosphate (AMP) to form adenosine.16 As
the major source of extracellular adenosine, CD73 controls
important physiological responses in inflammation, epithe-
lial transport, tissue barrier function, and hypoxia, among
others.16,17 Based on in vivo data using CD732/2 mice, it
was previously demonstrated that CD73 contributes to
ethanol-induced liver steatosis18 and thioacetamide- or
CCL4-induced liver fibrosis.
19 Using ex vivo and in vivo
approaches, we demonstrate that C3H and C57BL mice
have differences in expression and regulation of CD73 dur-
ing liver injury and that CD73 contributes toMDB forma-
tion in mice.
Materials and Methods
Antibodies. The following antibodies (Abs) were
used: rat anti-CD73 (R&D Systems, Minneapolis, MN)
for immunoblotting; anti-CD73 (TY/23; BD Bioscience,
San Jose, CA) for immunofluoresence (IF) staining; anti-
K8 Troma I (Developmental Studies Hybridoma Bank,
Iowa City, IA); anti-K8/K18 rabbit Ab 8592 for IF
staining of mouse K8/K1820; anti-DDK (Flag; OriGene
Technologies, Inc., Rockville, MD); mouse anti-Ub and
goat anti-p62 (Santa Cruz Biotechnology, Santa Cruz,
CA); rabbit anti-transglutaminase 2 (TG2; Thermo
Fisher Scientific Inc., Waltham, MA); and rabbit anti-
EEA1, anti-PDI, anti-RCAS1, and anti-LAMP1 (Cell
Signaling Technology, Danvers, MA) for immunostain-
ing of organelle markers.
Quantitative Polymerase Chain Reaction. RNA
extraction, quantitative real-time polymerase chain
reaction (qPCR), and data analysis were performed as
previously described15 using human and mouse gene-
specific primers (Supporting Table 1).
Human and Animal Liver Experiments. Human
liver specimens were biopsies from HCV and nonalco-
holic fatty liver disease (NAFLD) patients collected at
the University of Michigan (Ann Arbor, MI) under an
approved human subjects protocol. Information on
pathology findings is provided in Supporting Table 2.
MDB induction experiments in C3H/He (C3H) and
C57BL/6J (C57BL) mice were done as previously
described.12 CD732/2 mice in a C57BL background21
were provided by Dr. Linda Thompson (Oklahoma
Medical Research Foundation, Oklahoma City, OK).
Age- and sex-matched wild-type (WT) C57BL and
CD732/2 mice were used (2 control and 9 DDC-fed
mice [4 animals for 3 weeks and 5 animals for 3
months]) in the DDC experiment that was performed
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in duplicate, and as previously described.12 For metabo-
lomic analysis (3 mice/strain), mice were fasted for 5
hours, after which they were sacrificed and their livers
rapidly excised and snap-frozen. The left liver lobe from
each mouse was used in the metabolomic analysis (see
below). All mice received humane care and their use was
approved by, and performed in accord with, the univer-
sity committee on use and care of animals at the Univer-
sity of Michigan.
Metabolomics. Metabolomic analysis was performed
at the Michigan Regional Comprehensive Metabolomics
Resource Core (University of Michigan). Pulverized
mouse liver tissues were extracted with a methanol, ace-
tone, and acetonitrile mixture (1:1:1). For liquid chroma-
tography/mass spectrometry analysis of metabolites,
samples were separated using an Agilent 1200 analytical
HPLC on a Luna NH2 HILIC column, followed by
injection into the mass spectrometer (Agilent 6410 series
triple quadrupole with electrospray ionization source;
Agilent Technologies, Inc., Santa Clara, CA), which was
operated in negative mode. Data were processed by Mass-
Hunter workstation software (version B.04; Agilent).
Preparation of Tissue Lysates and Immunoblot-
ting. Total liver homogenates were prepared by
homogenizing tissues in 23 sample buffer (4% sodium
dodecyl sulfate [SDS], 10% 2-mercaptoethanol, 20%
glycerol, 0.004% bromophenol blue, and 0.125 M of
Tris-HCl; pH 6.8). Total lysates were used in immuno-
blottings for TG2, p62, K8, and ubiquitin. For radioim-
munoprecipitation (RIPA) buffer lysates (used in CD73
immunoblotting and enzyme activity), livers were
homogenized in ice-cold RIPA buffer (150 mM of
sodium chloride, 1% NP-40, 0.5% sodium deoxycho-
late, 0.1% SDS, and 50 mM of Tris; pH 8) with prote-
ase inhibitors. Lysates were resolved on gradient 4%-
20% SDS-PAGE (polyacrylamide gel electrophoresis)
gels, then transferred onto polyvinylidene difluoride
membranes, which were subsequently blocked (5% milk
in phosphate-buffered saline and 0.1% Tween-20) and
incubated with the designated Abs.
Biochemical Measurement of CD73 Enzymatic
Activity. CD73 activity was measured in mouse liver
RIPA lysates using a kit (BQ Kits, San Diego, CA). The
assay was based on a four-reaction sequence, beginning
with hydrolysis of 50-inosine monophosphate to form
inosine and ending with the generation of a quinone
dye from hydrogen peroxide (by-product of uric acid
synthesis), which was monitored spectrophotometrically
in a time-dependent manner. The assay’s specificity for
CD73, under our experimental conditions, was verified
using CD732/2 liver lysate controls.
CD73 Enzyme Histochemistry. CD73 activity in
fixed hepatocytes and tissue sections (6 lm) was done
using a modified version of a published protocol.22
Cells and tissue sections were fixed in 10% neutral
buffered formalin for 5 minutes at 4C, rinsed in 0.1
M of Tris-maleate (TM) buffer (pH 7.2), then incu-
bated in reaction medium (1 hour at 37C). Reaction
medium was prepared by first dissolving magnesium
chloride (10 mM) and lead nitrate (3.6 mM) in TM
buffer at 50C until the solution became clear, then
cooled to 37C. Tissue-nonspecific alkaline phospha-
tase inhibitor (levamisole; 5 mM) and substrate (AMP;
1 mM) were added before incubation. After incuba-
tion, reactions were stopped by several rinses with
water, followed by 1-minute incubation in sodium sul-
fide (1% w/v) and mounting in Prolong Gold reagent
with 40,6-diamidino-2-phenylindole (DAPI).
IF Staining and Confocal Imaging. After acetone
fixation (10 minutes, 220C), 6-lm-thick tissue sec-
tions were stained as previously described.15 CD73 com-
plementary DNA (cDNA) in pCMV6-Entry vector was
purchased from OriGene Technologies. Primary hepato-
cytes were isolated and transfected as described previ-
ously.15 Hepatocytes were transfected with CD73 for 24
hours, followed by a 24-hour treatment with DDC (100
lM), then fixed in methanol (10 minutes, 220C)
before immunostaining.
Results
Metabolomic Analysis of Livers From C3H and
C57BL Mice. We initially performed a targeted anal-
ysis for metabolic intermediates of glycolysis, tricarbox-
ylic acid (TCA) cycle, and nucleotide metabolism in
untreated C3H and C57BL mice (Table 1). The graph
data were presented and statistically analyzed using
Prism 5 software (GraphPad Software). Of the 21
metabolites assayed, adenosine triphosphate (ATP) and
guanosine monophosphate (GMP) showed statistically
significant differences (P < 0.05). We also performed
an unbiased analysis, which revealed differences in sev-
eral amino acids, carbohydrates, vitamins, and lipids
(Supporting Table 3), in addition to nucleotide inter-
mediates. Significant differences in the nucleobase ade-
nine (C3H<C57BL) and the nucleoside inosine
(C3H>C57BL) were observed (Fig. 1A). Based on
these findings, we focused on the ATP branch of the
purine-metabolism pathway (Fig. 1B) for further vali-
dation and mechanistic analysis.
We asked whether the two strains have differences
in the expression of enzymes involved in purine nucle-
otide synthesis, metabolism, and salvage. Although
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there are numerous enzymes that can exert control over
these pathways, the major ones are depicted in the sim-
plified schematic shown in Fig. 1B. Comparison of
messenger RNA (mRNA) levels showed significantly
lower levels of CD73 and PNP in C57BL livers (Fig.
1C). Because CD73 is upstream of PNP and its mRNA
in C57BL livers is only 25% of C3H livers, we chose
to study it in more detail. Importantly, we found a
striking decrease (<20% of control) in CD73 mRNA
in human liver biopsies from patients with fibrosis
resulting from HCV infection or NAFLD (Fig. 1D,E).
This was in stark contrast to increases in the following
reference genes: interferon-gamma (IFN-c) and C-X-C
motif chemokine 10 (CXCL10) in HCV23 and fatty-
acid-binding protein and collagen 1a1 in NAFLD.24
CD73 mRNA and Protein Are Markedly Higher
in C3H, Compared to C57BL, Livers. Quantitative
CD73 mRNA assessment revealed dramatically lower
levels in C57BL livers (Fig. 2A), which was reflected
in isolated hepatocytes (Fig. 2B) and paralleled by the
protein levels in C57BL (but not C3H) livers, as
assessed by immunoblotting of liver lysates (Fig. 2C)
and IF analysis of liver sections (Fig. 2D). Further-
more, DDC diminished CD73 activity in C3H and
C57BL livers, as measured by enzyme histochemistry
and compared to CD732/2 livers as a control (Fig.
2E). Prominent porphyria was evident in both strains
after DDC treatment (Fig. 2E, dark deposits high-
lighted by arrows). The increase in CD73 mRNA in
C3H DDC livers without an increase at the protein
and activity levels may be related to translational con-
trol or antibody reactivity masking.
CD73 protein expression was lost in isolated hepa-
tocytes as early as 1 hour postisolation (Fig. 3A) and
was still absent at 48 hours postisolation (not shown),
regardless of the mouse strain. Therefore, to study the
effects of DDC on CD73 ex vivo, we transfected
C57BL hepatocytes with the cDNA of flag-tagged
mouse CD73. After transfection, we detected a CD73
monomer (68 kD) and a dimer (140 kD; Fig.
3B), as expected, because endogenous CD73 exists as a
dimer on the plasma membrane.25 The ectopically
expressed CD73 exhibited both plasma membrane and
intracellular localization under normal conditions (Fig.
3C, left panel) and was enzymatically active (Fig. 3D).
However, upon DDC treatment, CD73 was lost from
the plasma membrane and accumulated in intracellular
granules (Fig. 3C, right panel). Costaining with differ-
ent organelle markers revealed partial colocalization
with resident proteins of the endoplasmic reticulum,
Golgi, and early endosomes, but not lysozomes (Sup-
porting Fig. 1), suggesting that the ability of CD73 to
proceed along the secretory pathway may be compro-
mised in the presence of DDC. Furthermore, there
was a complete loss of hepatocyte CD73 activity after
DDC treatment (Fig. 3E), reflecting the in vivo data.
Comparison of DDC-Induced MDB Formation in
WT and CD732/2 Mice. We assessed the effect of
3-week and 3-month DDC feeding in WT C57BL
(referred to as WT hereafter) and CD732/2 (in the
C57BL background) mice. DDC decreased CD73
activity in WT mice by 60%, as measured in the
detergent-soluble liver fractions using a biochemical
approach, as described in Materials and Methods (Fig.
4A). Serum alanine aminotransferase levels after DDC
were similarly elevated in WT and CD732/2 mice
(Supporting Fig. 2A). WT mice exhibited a time-
dependent increase in their liver/body-weight ratios
(Fig. 4B), a well-established effect of DDC feeding
that is the result of a combination of factors, such as
hepatocyte ballooning, ductular reaction, and porphy-
ria.1,3,26 Although liver enlargement also occurred in
DDC-treated CD732/2 mice, it was significantly less
Table 1. Metabolomic Comparison of Nucleotides, Glycosis,
and TCA Cycle Intermediates in C3H and C57BL Livers
C3H C57BL
Metabolite (nmol/mg Liver Tissue) P Value
LAC 4.7 6 0.2 3.4 6 0.9 0.23
MAL 0.0012 6 0.0002 0.0014 6 0.0003 0.56
FUM 0.12 6 0.06 0.16 6 0.03 0.56
F6P/G6P 0.20 6 0.01 0.20 6 0.02 1.00
CIT/ICIT 0.16 6 0.004 0.14 6 0.02 0.35
Pyr 0.21 6 0.01 0.19 6 0.02 0.43
2PG/3PG 0.026 6 0.003 0.019 6 0.003 0.15
aCoA 0.021 6 0.006 0.020 6 0.004 0.91
PEP 0.0065 6 0.002 0.0032 6 0.0006 0.21
FBP 0.024 6 0.02 0.0056 6 0.004 0.32
FAD 0.068 6 0.002 0.068 6 0.002 0.87
NAD 0.32 6 0.004 0.36 6 0.02 0.16
NADH 0.32 6 0.01 0.37 6 0.02 0.08
NADP 0.052 6 0.005 0.056 6 0.003 0.46
NADPH 0.34 6 0.3 0.42 6 0.4 0.87
AMP 2.26 6 0.009 2.6 6 0.15 0.08
ADP 0.56 6 0.02 0.58 6 0.02 0.64
ATP 0.12 6 0.003 0.10 6 0.003* 0.02
GMP 0.33 6 0.005 0.45 6 0.03* 0.01
GDP 0.097 6 0.05 0.037 6 0.02 0.28
GTP 0.011 6 0.009 0.0037 6 0.003 0.46
Abbreviations: LAC, lactate; MAL, malate; FUM, fumarate; F6P, fructose 6-
phosphate; G6P, glucose 6-phosphate; CIT, citrate; ICIT, isocitrate; Pyr, pyruvate;
2PG, 2-phosphoglycerate; 3PG, 3-phosphoglycerate; aCoA, acetyl coenzyme A;
PEP, phosphoenolpyruvate; FBP, fructose 1,6-biphosphate; FAD, flavin adenine
dinucleotide; NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide ade-
nine dinucleotide, reduced; NADP, nicotinamide adenine dinucleotide phos-
phate; NADPH, nicotinamide adenine dinucleotide phosphate, reduced; ADP,
adenosine diphosphate; GDP, guanosine diphosphate; GTP, guanosine
triphosphate.
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than WT mice after 3 months of DDC feeding (Fig.
4B). There were lower levels of the ubiquitin-binding
(and MDB component) protein, p62, in CD732/2 liv-
ers after 3 months of DDC feeding (Fig. 4C). We found
no evidence of CD73 and p62 colocalization in DDC-
treated livers (Supporting Fig. 2B). TG2 was significantly
up-regulated in both WT and CD732/2 mice (Fig. 4C)
in response to injury. The limited p62 induction in
CD732/2 livers after DDC feeding suggested that they
may exhibit fewer MDBs, compared to WT mice. This
was confirmed biochemically (Fig. 4D) by immunoblot-
ting analysis for high-molecular-mass K8 and ubiquitin
complexes that migrate near the top of the gel and repre-
sent cross-linked K8 and ubiquitin-containing species.3
These complexes were present in WT, but largely absent
from CD732/2, livers (Fig. 4D).
Ballooning degeneration in hepatocytes occurs with
concomitant loss of the K8/K18 cytoskeleton.4 There
were no significant differences in K8/K18 between
untreated CD732/2 mice, compared to untreated WT
mice (Supporting Fig. 2C). On the other hand, after
DDC treatment, there was a significant loss of the K8/
K18 filament network in WT livers, but not in
CD732/2 livers (Figure 5A). Histological analysis
showed that, whereas both WT and CD732/2 mice
displayed a significant response to DDC, including
porphyria, hypertrophy, and bile stasis, there was sig-
nificantly more cellular ballooning and steatosis present
in WT, compared to the knockout (KO), livers (Fig.
5B and Supporting Fig. 2D). Furthermore, MDBs
were mainly noted in WT livers (Fig. 5B, arrows).
Because only large MDBs are observed by hematoxylin
and eosin (H&E) staining,1 we asked whether
CD732/2 livers form smaller MDBs, only noted after
IF analysis of keratin and ubiquitin-containing aggre-
gates. As shown by the representative data in Fig. 6,
such aggregates were only present in WT, but not
CD732/2, livers (Fig. 6). Combined, these data dem-
onstrate that CD73 is an important mouse-strain-
related modulator of MDB formation.
Fig. 1. Differences in substrates and enzymes of the purine-metabolism pathway in C3H and C57BL livers. (A) Measurement of nt metabolism
intermediates using unbiased metabolomic analysis of the same C3H and C57BL livers as in Table 1 (n 5 3 livers/strain). *P < 0.05, two-way
analysis of variance. (B) Purine nt metabolites and the corresponding enzymes involved in their synthesis and metabolism. The ecto-apyrase,
CD39, converts extracellular ATP to AMP, which is, in turn, converted to extracellular adenosine by the ecto-50-nucleotidase, CD73. Intracellular
adenosine is converted to either adenine by purine nt phosphorylase (PNP) or to inosine by adenosine deaminase (ADA). Adenine phosphoribo-
syltransferase (APRT) regenerates AMP from adenine. PNP generates hypoxanthine from inosine, whereas xanthine oxidase (XO) generates xan-
thine and uric acid. (C) Comparison of mRNA levels of purine nt metabolism enzymes. C57BL liver mRNA values are expressed as fold change
relative to C3H livers. *P < 0.05; ***P < 0.001; unpaired t test (C3H versus C57BL). (D and E) Measurement of CD73 mRNA levels in human
HCV and NAFLD liver biopsies. Reference genes IFN-c and CXCL10 (HCV) and FABP4 and COL1A1 (NAFLD) are shown as positive controls. Val-
ues are expressed as fold change (log scale) over normal liver biopsies (2 controls).
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Discussion
We initiated our present study with a global
approach to examine differences in metabolic pathways
between MDB-susceptible and -resistant mice. The
results from the metabolomic assessment led us to
focus on the purine-metabolism pathway, from which
Fig. 2. Significantly decreased expression and activity of CD73 in C57BL mouse liver after DDC treatment. (A) Measurement of CD73 mRNA
in C3H and C57BL livers from untreated (control) and DDC-treated (3 months) mice. Values are expressed as fold difference from C3H control
livers. **P < 0.01; ***P < 0.001; two-way analysis of variance. (B) Measurement of CD73 mRNA in isolated hepatocytes from C3H and
C57BL mice. ***P < 0.001; unpaired t test. (C) CD73 immunoblotting of liver lysates from C3H and C57BL livers from untreated (control) and
DDC-treated (3 months) mice. Relative expression values are averaged for the 3 control and 4 DDC livers per strain and normalized to C3H con-
trol livers. O.D. 5 optical density. (D) IF detection of CD73 protein (green) with DAPI nuclei (blue) in C3H and C57BL livers from control and
DDC-treated (3 months) mice. Scale bar 5 50 lm. (E) AMPase activity in control and DDC-treated (3 months) C3H and C57BL livers. A loss of
CD73 enzymatic activity and porphyrin accumulation (arrows highlight porphyrin deposits) are observed after DDC treatment. CD732/2 AMPase
activity is shown, together with the corresponding DAPI-stained nuclei, as a negative control. Scale bar 5 100 lm.
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Fig. 3. DDC modulates CD73 localization in primary mouse hepatocytes. (A) IF detection of endogenous CD73 protein (red), which is largely
lost in freshly isolated hepatocytes (1 hour postisolation). Blue 5 DAPI-stained nuclei; scale bar 5 50 lm. (B) Flag immunobloting detection of
CD73 monomer (68 kD) and dimer (140 kD) after expression of flag-tagged mouse CD73 in hepatocytes . (C) Loss of plasma membrane
CD73 (green) after DDC treatment (100 lM for 24 hours) of primary hepatocytes. Blue 5 DAPI-stained nuclei; scale bars 5 20 lm. (D)
AMPase activity in control and Flag-CD73-transfected hepatocytes showing that overexpressed CD73 is enzymatically active. Blue 5 DAPI-
stained nuclei. Lower right two panels represent a magnified view of the area demarcated by a white dotted line in the lower left panel. Arrows
point out plasma membrane-associated AMPase activity. Scale bar 5 200 lm. (E) AMPase activity in Flag-CD73-transfected hepatocytes that
were treated with dimethyl sulfoxide (DMSO) vehicle or 100 lM DDC for 24 hours showing DDC-induced inhibition of CD73 enzymatic activity.
Blue 5 DAPI-stained nuclei; scale bar 5 200 lm.
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Fig. 4. Comparison of biochemical markers of liver injury in DDC-treated WT and CD732/2 mice. (A) Measurement of CD73 activity in livers
from untreated (control) and DDC-treated (3 months) WT and CD732/2 mice. (B) CD732/2 mice had lower liver/body-weight ratio after 3
months of DDC treatment, relative to WT mice. ***P < 0.001; two-way analysis of variance. (C) Immunoblotting analysis of p62 (MDB compo-
nent) and TG2 in total liver lysates of WT and CD732/2 mice. (D) Immunoblottings of K8 and ubiquitin (Ub) from total liver lysates of WT and
CD732/2 mice showing the presence of high-molecular-mass (HMM) K8 and Ub complexes in WT, but not CD732/2, mice after DDC treatment
for 3 months.
Fig. 5. Comparison of DDC-induced liver injury in WT and CD732/2 mice. (A) Double IF staining for K8/K18 (green) and DAPI nuclei (blue)
shows that the K8/K18 filament network is preserved in CD732/2 mouse livers relative to WT livers after DDC treatment for 3 months. Scale
bars 5 50 lm. (B) H&E staining shows more prominent steatosis, cellular ballooning, and MDBs (marked by arrows) in WT, relative to CD732/2,
mice. Results are representative from 3 separate WT and 4 CD732/2 mouse livers. Scale bars 5 100 lm (control) and 50 lm (DDC).
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we identified the ectonucleotidase, CD73, as a pro-
moting factor for MDB formation in mice.
Our findings coincide with recent studies high-
lighting a role for CD73 in liver pathophysiology.
In mouse models of liver fibrosis triggered by thioa-
cetamide or CCl4, the absence of CD73 is protec-
tive.19 On the other hand, it was previously shown
that CCl4-induced liver damage and concanavalin A-
induced liver injury and release of proinflammatory
cytokines were exacerbated in adenosine receptor
2A-deficient mice.27 In further support of a profi-
brogenic role of CD73 in mouse liver, CD73 is
transcriptionally up-regulated in activated hepatic
stellate cells during myofibroblast differentiation.28
However, in our present findings, we show that
CD73 mRNA is dramatically decreased in fibrotic
human livers (regardless of etiology or fibrosis sever-
ity). Potential CD73 expression changes during vari-
ous stages of human disease progression that are not
always reflected in experimental models and the
presence of other factors, such as inflammation and
steatosis, may be behind these observations. CD73
activity and adenosine receptor activation have also
been implicated in ethanol-induced hepatic steatosis
in mice.18 Specifically, CD732/2 mice are protected
from developing fatty liver.18 Given that MDBs are
commonly observed in steatohepatitis,1,14 our find-
ings that CD732/2 mice have less steatosis and are
protected from MDBs align with these previous
studies.
Fig. 6. IF analysis of
MDBs in livers from WT and
CD732/2 mice. Freshly frozen
tissue sections from control
and DDC-treated (3 months)
WT and C57BL mice were
stained with Abs against K8/
K18 (red) and ubiquitin
(green). MDBs (marked by
arrows) are only present in
WT livers after DDC treatment.
Shown are representative
results from three separate
WT and four CD732/2 mouse
livers. Scale bars 5 50 lm.
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Although our data demonstrate a role for CD73 in
MDB formation, the use of the full-body CD73 KO
does not allow us to discern whether this involves a
hepatocyte-intrinsic mechanism or is influenced by
CD73 on other cells (e.g., immune or endothelial).
CD73 is expressed on multiple cell types, including
leukocytes, myofibroblasts, endothelial, and epithelial
cells.16,28 A previous study using ferritin immunoelec-
tron microscopy compared the expression and plasma
membrane distribution of CD73 in endothelial cells
(ECs) and hepatocytes in rat liver.29 This study found
that the bile canalicular surface of hepatocytes had
approximately 4-fold higher density of CD73, relative
to the sinusoidal surface,29 which might be expected
for a glycosylphosphatidylinositol-anchored protein.17
Relative to hepatocytes, ECs were estimated to have
approximately 60% fewer CD73 molecules.29
Given the direct effects of DDC on CD73 localiza-
tion, we posit that at least some of the in vivo findings
are directly attributable to hepatocyte CD73. A previous
study estimated that only 48% of hepatocyte CD73
activity is on the cell surface, in contrast to 75%-79% of
the CD73 activity in adipocytes and lymphocyte being
accounted for by the cell-surface-localized enzyme.30 The
intracellular CD73 fraction is membrane associated and
enzymatically active, but latent (available to substrate
only upon cell breakage), and the exact organelle com-
partments that host intracellular CD73 are unclear.30
There is dynamic cycling of the intracellular CD73 pool
to the plasma membrane, but only a small fraction
(3%) of it is thought to be lysosomal.31 If and how the
cellular distribution of CD73 in hepatocytes affects intra-
cellular protein aggregation remains to be investigated.
Protein aggregation is a common disease mechanism
for multiple organ pathologies and is characterized by
protein misfolding and proteasomal inhibition. Uncov-
ering molecular modulators that regulate protein
aggregation will not only provide insight into potential
tissue- and cell-type-specific pathways, but may also
shed light on individual susceptibility to intracellular
inclusions. To our knowledge, this is the first report
that alterations in purine metabolism and CD73 activ-
ity act as modulators of protein aggregation. Given the
widespread expression and functional significance of
CD73,16 these findings may hold true in other tissues
and cell types. Furthermore, our findings point to dra-
matic differences in CD73 mRNA and protein levels
between two different mouse strains. It would be rele-
vant to determine whether differences in CD73 expres-
sion are also present in genetically diverse human
populations and whether CD73 contributes to human
MDB formation or susceptibility to liver disease.
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